Mass Tort Advertising Campaign

Dupixent Marketing & Claimant Acquisition

Dupixent (dupilumab) litigation is an emerging pharmaceutical docket around one of the world's best-selling drugs. Filings allege that in some patients treated for what was diagnosed as eczema, Dupixent masked or accelerated cutaneous T-cell lymphoma (CTCL) — a cancer whose early presentation mimics the skin conditions the drug treats — and that the manufacturers failed to warn of that risk. Separate claims involve serious ocular injuries reported with the drug's use.

For plaintiff firms, this is a ground-floor tort: an enormous treated population, a severe alleged injury, and filings early enough that case acquisition is essentially uncontested.

Book a strategy call All tort campaigns

Dupixent at a glance

Substance / mechanism
Dupilumab
Manufacturer(s)
Sanofi / Regeneron
Associated injuries
Lymphoma Progression / Ocular Injuries
Litigation status
DEVELOPING
Campaign intake
Open

The litigation landscape

The core fact pattern gives the litigation its shape: CTCL is routinely misdiagnosed as eczema or atopic dermatitis for years, and plaintiffs allege that treating that misdiagnosed population with an immune-modulating biologic delayed the true diagnosis while the lymphoma advanced. Because Dupixent's prescribing base runs into the millions worldwide, even a rare alleged effect defines a meaningful claimant population.

The docket is early — individual filings rather than consolidation — which historically is when firms build inventory at the most favorable economics, before the tort has a national advertising footprint.

Who a campaign targets

Screening criteria firms typically evaluate in Dupixent matters include:

  • Documented Dupixent use, most commonly for eczema or atopic dermatitis
  • A subsequent CTCL or related lymphoma diagnosis, particularly where skin symptoms predated and continued through treatment
  • Timeline supporting delayed diagnosis or progression during the treatment period
  • For ocular claims: serious documented eye injuries during use; and for all claims, viability under the state's limitations rules

How MTAA runs Dupixent campaigns

Early-tort advertising rewards education-led creative: the connection between an eczema drug and a lymphoma diagnosis is not one patients make on their own, so campaigns that explain the misdiagnosis pattern generate inquiries no competitor is yet contesting. The treated population is large, identifiable, and reachable through health-interest targeting.

MTAA is running Dupixent as an early-position campaign with screening built around the diagnosis-timeline questions that determine case viability.

Pricing

Mass Tort Ad Agency runs Dupixent campaigns on the same transparent model as every tort: actual Meta ad spend at cost plus a flat 15% management fee, a one-time $1,000 setup fee per tort, and $100 per signed retainer for CloudIntake qualification. No per-case markups, no lead resale, and the firm owns its ad account, pixel, creative, and claimant data.

Dupixent advertising — common questions

What do Dupixent lawsuits allege?
Primarily that the drug masked or accelerated cutaneous T-cell lymphoma in patients treated for presumed eczema — a cancer whose early stages mimic the conditions Dupixent treats — with separate claims involving serious ocular injuries. These are allegations in developing litigation.
Why does the misdiagnosis pattern matter?
Because it defines the claimant: someone treated for years for eczema whose eventual CTCL diagnosis suggests the cancer was present and progressing during treatment. The timeline in the medical records is the case.
How early is this tort?
Ground floor — individual filings, no consolidation, minimal competing advertising. That combination is historically when signed-case economics are at their best for firms willing to move first.
How does MTAA screen these claims?
Diagnosis-timeline first: Dupixent use, the presumed-eczema history, and the subsequent lymphoma diagnosis, all record-provable. Ask for current early-tort benchmarks on our market data page.

Ready to run Dupixent campaigns?

We build, run, and qualify Dupixent claimant-acquisition campaigns end to end. Book a call and we'll walk you through the creative, audience, and intake plan.

Book a strategy call